[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574188":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":156,"collaborators":19,"id":158,"slug":19,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":19,"eligibilityCriteria":163,"healthyVolunteers":159,"sex":164,"minAge":165,"maxAge":19,"enrollmentInfo":166,"targetDuration":19,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":185,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-95","EXPERIMENTAL","Phase 1a: Dose Escalation - each dose cohort will assess toxicity 28 days following the first dose of CT95 anticipate a total of 8 dose cohorts.\n\nPhase 1b: Dose Expansion - approximately 80 participants will be evaluated in 2-4 indication-specific expansion cohorts.",[13],"Drug: CT-95",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant\u002Fphysician decision.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Karen Chagin, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Context Clinical Development","CONTACT","267-225-7416","cntx-ct95-101@contexttherapeutics.com",[31,49,63,77,91,106,116,129,143],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Context Investigational Site","RECRUITING","Denver","Colorado","80218","United States",{"type":39,"coordinates":40},"Point",[41,42],-104.9847,39.73915,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":19,"email":48},"Front Desk","720-754-2610","CANN.DDUDenverGeneral@SarahCannon.com",{"facility":32,"status":33,"city":50,"state":51,"zip":52,"country":37,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Chicago","Illinois","60637",{"type":39,"coordinates":54},[55,56],-87.65005,41.85003,{"lat":56,"lon":55},[59],{"name":60,"role":27,"phone":61,"phoneExt":19,"email":62},"Cancer Clinical Trials","773-702-6233","Cancerclinicaltrials@bsd.uchicago.edu",{"facility":32,"status":33,"city":64,"state":65,"zip":66,"country":37,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Grand Rapids","Michigan","49546",{"type":39,"coordinates":68},[69,70],-85.66809,42.96336,{"lat":70,"lon":69},[73],{"name":74,"role":27,"phone":75,"phoneExt":19,"email":76},"Ashley Spagnuolo","616-954-5552","ashley.spagnuolo@startresearch.com",{"facility":32,"status":33,"city":78,"state":79,"zip":80,"country":37,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Hackensack","New Jersey","07601",{"type":39,"coordinates":82},[83,84],-74.04347,40.88593,{"lat":84,"lon":83},[87],{"name":88,"role":27,"phone":89,"phoneExt":19,"email":90},"Oncology Clinical Research Referral Office","551-996-1777","OncologyResearchReferral@hmhn.org",{"facility":92,"status":33,"city":93,"state":94,"zip":95,"country":37,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":39,"coordinates":97},[98,99],-75.16362,39.95238,{"lat":99,"lon":98},[102],{"name":103,"role":27,"phone":104,"phoneExt":19,"email":105},"Andrea Standish","215-662-2419","Andrea.Standish@Pennmedicine.upenn.edu",{"facility":32,"status":33,"city":93,"state":94,"zip":107,"country":37,"cosmosGeoPoint":108,"geoPoint":110,"contacts":111},"19107",{"type":39,"coordinates":109},[98,99],{"lat":99,"lon":98},[112],{"name":113,"role":27,"phone":114,"phoneExt":19,"email":115},"Ask Phase1","215-586-0199","AskPhase1@jefferson.edu",{"facility":32,"status":33,"city":117,"state":118,"zip":119,"country":37,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Nashville","Tennessee","37203",{"type":39,"coordinates":121},[122,123],-86.78444,36.16589,{"lat":123,"lon":122},[126],{"name":127,"role":27,"phone":128,"phoneExt":19,"email":19},"Sarah Cannon Research Institute","844-482-4812",{"facility":32,"status":33,"city":130,"state":131,"zip":132,"country":37,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"San Antonio","Texas","78229",{"type":39,"coordinates":134},[135,136],-98.49363,29.42412,{"lat":136,"lon":135},[139],{"name":140,"role":27,"phone":141,"phoneExt":19,"email":142},"Clinical Trial Navigator","210-580-9521","jgeorg@nextoncology.com",{"facility":32,"status":33,"city":130,"state":131,"zip":132,"country":37,"cosmosGeoPoint":144,"geoPoint":146,"contacts":147},{"type":39,"coordinates":145},[135,136],{"lat":136,"lon":135},[148,152],{"name":149,"role":27,"phone":150,"phoneExt":19,"email":151},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"name":153,"role":27,"phone":19,"phoneExt":154,"email":155},"Christina Santana","210-593-5205","csantana@startresearch.com",{"type":157,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100574188",false,"NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression","Phase 1a\u002F1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression","Inclusion Criteria:\n\n* ECOG 0 or 1\n* Subjects with evaluable disease per RECIST 1.1 or mRECIST\n* Subjects with adequate organ function.\n* Subjects with advanced cancers associated with mesothelin expression\n\nExclusion Criteria:\n\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.\n* Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy\n* Concurrent participation in another investigational clinical trial.\n* Evidence of leptomeningeal disease","ALL","18 Years",{"count":167,"type":168},70,"ESTIMATED","INTERVENTIONAL",[171],"PHASE1","This is a Phase 1a\u002F1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.",[174,175,176,177,178,179,180,181,182,183,184],"Mesothelin-Expressing Tumors","Epithelial Ovarian Cancer","Malignant Pleural Mesothelioma, Advanced","Malignant Peritoneal Mesothelioma, Advanced","Pancreatic Adenocarcinoma Advanced or Metastatic","Lung Adenocarcinoma Metastatic","Cholangiocarcinoma Advanced","Cholangiocarcinoma Non-resectable","Mesothelin-expressing Advanced Cancers","Mesothelin-positive Advanced Malignant Solid Tumors","Colorectal Cancer",[186,9,187,188,189],"Phase 1 Dose Escalation Study","Advanced, recurrent cancers","Unresectable, metastatic cancers","Cancers associated with mesothelin expression","2026-06-10",{"date":192,"type":193},"2026-06-12","ACTUAL",{"date":195,"type":193},"2025-03-31",{"date":197,"type":168},"2028-12",{"name":5,"class":6},9]